Market Closed -
Nasdaq Stockholm
08:59:38 31/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1,643
SEK
|
+1.08%
|
|
-1.76%
|
+21.39%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,32,331
|
1,31,461
|
1,81,878
|
2,10,243
|
2,09,128
|
2,40,446
|
-
|
-
|
Enterprise Value (EV)
1 |
1,44,340
|
1,43,328
|
2,06,261
|
2,33,166
|
2,31,638
|
2,60,866
|
2,54,161
|
2,47,630
|
P/E ratio
|
97.9
x
|
41
x
|
1,468
x
|
64.3
x
|
35.4
x
|
27.4
x
|
23.3
x
|
21
x
|
Yield
|
2.78%
|
2.8%
|
2.44%
|
2.14%
|
2.15%
|
1.98%
|
2.09%
|
2.18%
|
Capitalization / Revenue
|
5.43
x
|
4.94
x
|
4.86
x
|
4.74
x
|
4.57
x
|
4.66
x
|
4.33
x
|
4.1
x
|
EV / Revenue
|
5.92
x
|
5.38
x
|
5.51
x
|
5.26
x
|
5.06
x
|
5.05
x
|
4.58
x
|
4.22
x
|
EV / EBITDA
|
21.6
x
|
17.2
x
|
27.2
x
|
25.2
x
|
17.1
x
|
14.8
x
|
12.6
x
|
11.3
x
|
EV / FCF
|
72.5
x
|
37.3
x
|
42.3
x
|
26.7
x
|
25.8
x
|
30
x
|
21.6
x
|
18.2
x
|
FCF Yield
|
1.38%
|
2.68%
|
2.36%
|
3.74%
|
3.88%
|
3.33%
|
4.62%
|
5.51%
|
Price to Book
|
10
x
|
8.41
x
|
4.24
x
|
5.67
x
|
5.38
x
|
5.81
x
|
5.21
x
|
4.6
x
|
Nbr of stocks (in thousands)
|
13,11,913
|
13,12,660
|
15,49,159
|
15,49,528
|
15,49,926
|
15,50,235
|
-
|
-
|
Reference price
2 |
100.9
|
100.1
|
117.4
|
135.7
|
134.9
|
155.1
|
155.1
|
155.1
|
Announcement Date
|
14/02/20
|
11/02/21
|
10/02/22
|
09/02/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
24,384
|
26,617
|
37,417
|
44,351
|
45,811
|
51,618
|
55,500
|
58,701
|
EBITDA
1 |
6,686
|
8,311
|
7,586
|
9,237
|
13,580
|
17,596
|
20,095
|
21,910
|
EBIT
1 |
6,436
|
7,340
|
9,928
|
13,350
|
14,534
|
16,800
|
19,008
|
20,658
|
Operating Margin
|
26.39%
|
27.58%
|
26.53%
|
30.1%
|
31.73%
|
32.55%
|
34.25%
|
35.19%
|
Earnings before Tax (EBT)
1 |
1,548
|
3,916
|
-265
|
2,501
|
6,899
|
10,901
|
13,037
|
14,422
|
Net income
1 |
1,335
|
3,196
|
112
|
3,288
|
5,961
|
8,844
|
10,380
|
11,620
|
Net margin
|
5.47%
|
12.01%
|
0.3%
|
7.41%
|
13.01%
|
17.13%
|
18.7%
|
19.8%
|
EPS
2 |
1.030
|
2.440
|
0.0800
|
2.110
|
3.810
|
5.667
|
6.659
|
7.374
|
Free Cash Flow
1 |
1,990
|
3,838
|
4,872
|
8,717
|
8,984
|
8,684
|
11,745
|
13,640
|
FCF margin
|
8.16%
|
14.42%
|
13.02%
|
19.65%
|
19.61%
|
16.82%
|
21.16%
|
23.24%
|
FCF Conversion (EBITDA)
|
29.76%
|
46.18%
|
64.22%
|
94.37%
|
66.16%
|
49.35%
|
58.45%
|
62.26%
|
FCF Conversion (Net income)
|
149.06%
|
120.09%
|
4,350%
|
265.12%
|
150.71%
|
98.2%
|
113.15%
|
117.38%
|
Dividend per Share
2 |
2.800
|
2.800
|
2.870
|
2.900
|
2.900
|
3.078
|
3.243
|
3.377
|
Announcement Date
|
14/02/20
|
11/02/21
|
10/02/22
|
09/02/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
12,011
|
-
|
11,390
|
10,771
|
-
|
10,982
|
11,207
|
-
|
10,879
|
11,416
|
11,492
|
12,024
|
12,679
|
12,574
|
12,975
|
13,480
|
13,530
|
13,805
|
EBITDA
1 |
-
|
-
|
-
|
1,900
|
-
|
2,187
|
1,896
|
-
|
2,579
|
2,574
|
-
|
-
|
3,732
|
-
|
-
|
-
|
4,396
|
4,404
|
5,260
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
3,318
|
-
|
3,961
|
3,365
|
-
|
3,413
|
2,610
|
-
|
3,946
|
4,291
|
3,545
|
2,752
|
4,310
|
4,027
|
4,356
|
3,974
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
27.62%
|
-
|
34.78%
|
31.24%
|
-
|
31.08%
|
23.29%
|
-
|
36.27%
|
37.59%
|
30.85%
|
22.89%
|
33.99%
|
32.02%
|
33.57%
|
29.48%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-636
|
-
|
553
|
247
|
-
|
922
|
778
|
-
|
2,262
|
2,088
|
1,652
|
897
|
2,800
|
2,361
|
2,740
|
3,099
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-347
|
-
|
386
|
360
|
-
|
1,640
|
901
|
-
|
1,803
|
1,818
|
1,378
|
959
|
2,179
|
2,092
|
2,450
|
2,493
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-2.89%
|
-
|
3.39%
|
3.34%
|
-
|
14.93%
|
8.04%
|
-
|
16.57%
|
15.93%
|
11.99%
|
7.98%
|
17.19%
|
16.64%
|
18.88%
|
18.5%
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.2200
|
-
|
0.2500
|
0.2300
|
-
|
1.050
|
0.5800
|
-
|
1.160
|
1.170
|
0.8900
|
0.6200
|
1.410
|
1.341
|
1.569
|
1.600
|
-
|
-
|
Dividend per Share
2 |
0.9000
|
1.900
|
0.9000
|
1.970
|
1.970
|
-
|
0.9300
|
0.9300
|
-
|
1.970
|
1.970
|
-
|
0.9300
|
-
|
1.970
|
-
|
0.8875
|
0.7750
|
1.438
|
0.8750
|
0.8750
|
Announcement Date
|
30/07/20
|
11/02/21
|
29/07/21
|
10/02/22
|
10/02/22
|
29/04/22
|
29/07/22
|
29/07/22
|
10/11/22
|
09/02/23
|
09/02/23
|
27/04/23
|
28/07/23
|
09/11/23
|
08/02/24
|
25/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
12,009
|
11,867
|
24,383
|
22,923
|
22,510
|
20,420
|
13,715
|
7,184
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.796
x
|
1.428
x
|
3.214
x
|
2.482
x
|
1.658
x
|
1.16
x
|
0.6825
x
|
0.3279
x
|
Free Cash Flow
1 |
1,990
|
3,838
|
4,872
|
8,717
|
8,984
|
8,684
|
11,745
|
13,640
|
ROE (net income / shareholders' equity)
|
35.6%
|
36.7%
|
27.5%
|
27.2%
|
29.8%
|
30%
|
31.5%
|
30.7%
|
ROA (Net income/ Total Assets)
|
2.19%
|
4.99%
|
8.77%
|
3.26%
|
11.5%
|
9.36%
|
10.6%
|
11.4%
|
Assets
1 |
61,015
|
64,053
|
1,277
|
1,00,924
|
51,935
|
94,518
|
98,020
|
1,01,725
|
Book Value Per Share
2 |
10.10
|
11.90
|
27.70
|
23.90
|
25.10
|
26.70
|
29.70
|
33.70
|
Cash Flow per Share
2 |
2.280
|
3.660
|
4.180
|
6.290
|
6.620
|
8.540
|
10.40
|
11.60
|
Capex
1 |
979
|
961
|
1,091
|
1,091
|
1,361
|
1,990
|
1,957
|
1,935
|
Capex / Sales
|
4.01%
|
3.61%
|
2.92%
|
2.46%
|
2.97%
|
3.86%
|
3.53%
|
3.3%
|
Announcement Date
|
14/02/20
|
11/02/21
|
10/02/22
|
09/02/23
|
08/02/24
|
-
|
-
|
-
|
Last Close Price
155.1
USD Average target price
172
USD Spread / Average Target +10.90% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +9.78% | 210B | | -5.52% | 206B | | +6.17% | 164B | | -0.45% | 162B |
Other Pharmaceuticals
|